Table 2 Characteristics of studies included in the meta-analysis
Author | Year | Country | Sex (M/F) | Age | Surgery | ASA grade | Outcomes | Propofol group | Sevoflurane group | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
Method | No. | Method | No. | ||||||||
Yu et al. | 2012 | China | 44 /36 | 68.8 ± 3.8 | Lung cancer operation | I~II | ①②③④⑤⑥ | Induction: midazolam, fentanyl, rocuronium, etomidate; Maintain: propofol | 40 | Induction: midazolam, fentanyl, rocuronium, etomidate; Maintain: sevoflurane | 40 |
Tang et al. | 2014 | China | 38 /32 | 70.0 ± 11.7 | Lung cancer operation | I~II | ①②③④⑤⑥ | Induction: etomidate, midazolam, fentanyl, rocuronium; Maintain: propofol | 35 | Induction: etomidate, midazolam, fentanyl, rocuronium; Maintain: sevoflurane | 35 |
Sun et al. | 2014 | China | 77 /29 | 72.2 ± 2.6 | Lung cancer operation | N | ①②③④⑤⑥ | Induction: fentanyl and vecuronium bromide; Maintain: propofol 2~4 mg/kg/min | 53 | Induction: fentanyl and vecuronium bromide; Maintain: sevoflurane | 53 |
Cui et al. | 2015 | China | 94 /76 | 69 ± 12.9 | Lung cancer operation | N | ①③⑤⑥ | Induction: fentanyl, etomidate, vecuronium bromide; Maintain: propofol 2~4 mg/kg/min | 80 | Induction: fentanyl, etomidate, vecuronium bromide; Maintain: sevoflurane 1%~ 3% | 80 |
Zhang et al. | 2016 | China | 101 /91 | 60.0 ± 6.4 | Lung cancer operation | N | ①③④⑥ | Induction: midazolam, fentanyl, rocuronium, etomidate; Maintain: propofol | 96 | Induction: midazolam, fentanyl, rocuronium, etomidate; Maintain: sevoflurane | 96 |
Wang H et al. | 2015 | China | 41 /31 | 73.5 ± 2.8 | Lung cancer operation | I~II | ①②③④⑤⑥ | Induction: unified rapid induction; Maintain: propofol | 36 | Induction: unified rapid induction; Maintain: sevoflurane | 36 |
Wang F et al. | 2017 | China | 32 /18 | 72.5 ± 3.0 | Lung cancer operation | N | ①②③④⑤⑥ | Induction: midazolam, fentanyl, rocuronium, etomidate; Maintain: propofol | 50 | Induction: midazolam, fentanyl, rocuronium, etomidate; Maintain: sevoflurane | 50 |
Zhao et al. | 2014 | China | 80 /30 | 73.5 ± 2.0 | Lung cancer operation | I~II | ①②③④⑤⑥ | Induction: fentanyl and vecuronium bromide; Maintain: propofol 2~4 mg/kg/min | 50 | Induction: fentanyl and vecuronium bromide; Maintain: sevoflurane | 60 |
Chen et al. | 2015 | China | 43 /35 | 69.2 ± 3.2 | Lung cancer operation | N | ①②③④⑤⑥ | Induction: midazolam, propofol, fentanyl and vecuronium bromide; Maintain: propofol 6~10 mg/kg/min | 39 | Induction: midazolam, propofol, fentanyl and vecuronium bromide; Maintain: sevoflurane | 39 |
Huang et al. | 2015 | China | 50 /40 | 68.2 ± 1.3 | Lung cancer operation | N | ①②③④⑤⑥ | Induction: rocuronium, fentanyl, midazolam, etomidate; Maintain: propofol | 45 | Induction: rocuronium, fentanyl, midazolam, etomidate; Maintain: sevoflurane | 45 |
Lin et al. | 2017 | China | 54/40 | 68.23 ± 1.32 | Lung cancer operation | I~II | ①②③④⑥ | Induction: propofol, midazolam, vecuronium, fentanyl; Maintain: propofol | 40 | Induction: propofol, midazolam, vecuronium, fentanyl; Maintain: sevoflurane | 54 |
Zhang et al. | 2017 | China | 41/29 | P: 74.8 ± 2.1; S: 74.3 ± 2.5 | Lung cancer operation | I~II | ②③④ | Induction: fentanyl, etomidate, midazolam, rocuronium; Maintain: propofol | 35 | Induction: fentanyl, etomidate, midazolam, rocuronium; Maintain: sevoflurane | 35 |
Yang et al. | 2017 | China | 84/36 | 71.9 ± 2.5 | Lung cancer operation | N | ①②③④⑤⑥ | Induction: unified rapid induction; Maintain: propofol | 60 | Induction: unified rapid induction; Maintain: sevoflurane | 60 |
Tian et al. | 2017 | China | 38/24 | P: 68.3 ± 13.5; S: 65.5 ± 16.2 | Lung cancer operation | I~II | ①③⑥ | Induction: midazolam, fentanyl, propofol; Maintain: propofol | 31 | Induction: midazolam, fentanyl, sevoflurane; Maintain: propofol | 31 |